Deutsche Bank Reiterates Buy on Achillion Pharmaceuticals (ACHN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Deutsche Bank Reiterates Buy on Achillion Pharmaceuticals (ACHN)

FBR Capital Says Achillion's (ACHN) Nuc Has Greatest Potency Versus Gilead's (GILD) Sovaldi in the GT3 HCV Subtype

October 1, 2014 1:06 PM EDT

FBR Capital analyst Andrew Beren offered some positive comments on Achillion Pharmaceuticals (NASDAQ: ACHN) moments ago noting abstracts from AASLD showcasing preclinical data for Achillions ACH-3422 suggest that the NS5B nucleotide (nuc) inhibitor may have the greatest potency versus Gileads Sovaldi in the GT3 HCV subtype (7-fold as potent).

"Importantly, we view the GT3 subtype as the genotype with the greatest unmet medical need currently, as it requires extended duration... More

Achillion Pharma (ACHN), Novavax (NVAX) Lower as Johnson & Johnson Acquires Alios BioPharm.

September 30, 2014 10:14 AM EDT

Achillion Pharma (NASDAQ: ACHN) is down 4% early amid investors concern after Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire privately-held Alios BioPharma, not Achillion or Novavax (NASDAQ:... More